BS
Boston Scientific
BSX · NYSE
$47.81 +1.82% (+$0.86)
1M -5.27%
Market Cap $71.1B
P/E Ratio 19.38x
Div. Yield -
ROE 14.90%
Bulios Fair Price
$41.69
12.8% downside
Current Price
$47.81
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BSX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
64 /100
Fair P/E 19.38x
EV/EBITDA 14.63x
PEG 0.44x
Growth
97 /100
Growing EPS growth 63.25%
Rev. growth 16.54%
Book val. growth 11.30%
Profitability
95 /100
Strong Gross margin 71.16%
Net margin 17.47%
FCF margin 17.27%
Quality
61 /100
Average ROIC 10.57%
ROE 14.90%
Asset turnover 0.46x
Debt
74 /100
Low Debt/Equity 0.51x
Current ratio 1.24x
Net debt/EBITDA 2.13x
Stability
72 /100
Stable Beta 0.57x
Rev. volatility 3.89%
Profitable years 5
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BSX
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Michael F. Mahoney
Employees
59,000
Headquarters
Marlborough
Upcoming events
28 OCT
Earnings
Upcoming earnings report